Developing the ideal inhaled corticosteroid

Chest

Volumn 130, Issue 1 SUPPL., 2006, Pages 54S-64S

  Cerasoli Jr , Franklin ^a  

^a ALTANA Pharma US   (United States)

Author keywords

Asthma; Ciclesonide; Inflammation; Inhaled corticosteroids

Indexed keywords

BECLOMETASONE DIPROPIONATE; BUDESONIDE; CICLESONIDE; CORTICOSTEROID; DEXAMETHASONE; FLUNISOLIDE; FLUTICASONE PROPIONATE; GLUCOCORTICOID RECEPTOR; HYDROCORTISONE; METHACHOLINE; MOMETASONE FUROATE; TRIAMCINOLONE ACETONIDE;

ADRENAL INSUFFICIENCY; ASTHMA; BINDING AFFINITY; CANDIDIASIS; CONFERENCE PAPER; CORTICOSTEROID INDUCED OSTEOPOROSIS; CORTICOSTEROID THERAPY; DISEASE EXACERBATION; DRUG BIOAVAILABILITY; DRUG EFFICACY; DRUG PROTEIN BINDING; DRUG RECEPTOR BINDING; DRUG SAFETY; FORCED EXPIRATORY VOLUME; HOARSENESS; HUMAN; HYDROCORTISONE BLOOD LEVEL; HYDROCORTISONE URINE LEVEL; HYPOTHALAMUS HYPOPHYSIS ADRENAL SYSTEM; INFLAMMATION; LONG TERM EXPOSURE; LUNG FUNCTION TEST; METERED DOSE INHALER; MONOTHERAPY; PATIENT COMPLIANCE; PRIMARY MEDICAL CARE; PRIORITY JOURNAL; THROAT IRRITATION; THRUSH; TREATMENT OUTCOME;

EID: 33746311831     PISSN: 00123692     EISSN: None     Source Type: Journal    
DOI: 10.1378/chest.130.1_suppl.54S     Document Type: Conference Paper

References (67)

1. Wardlaw AJ, Brightling CE, Green R, et al. New insights into the relationship between airway inflammation and asthma. Clin Sci 2002; 103:201-211
2. Bousquet J, Jeffery PK, Busse WW, et al. Asthma: from bronchoconstriction to airways inflammation and remodeling. Am J Respir Crit Care Med 2000; 161:1720-1745
3. Jeffery PK, Laitinen A, Venge P. Biopsy markers of airway inflammation and remodelling. Respir Med 2000; 94(suppl): S9-S15
4. Tattersfield AE, Knox AJ, Britton JR, et al. Asthma. Lancet 2002; 360:1313-1322
5. Georgitis JW. The 1997 asthma management guidelines and therapeutic issues relating to the treatment of asthma. Chest 1999; 115:210-217
6. Barnes PJ. Pathophysiology of asthma. Br J Clin Pharmacol 1996; 42:3-10
7. Kelly HW. Potential adverse effects of the inhaled corticosteroids. J Allergy Clin Immunol 2003; 112:469-478
8. Sorkness CA. Establishing a therapeutic index for the inhaled corticosteroids: part II. J Allergy Clin Immunol 1998; 102: 552-564
9. Lipworth BJ. Systemic adverse effects of inhaled corticosteroid therapy: a systematic review and meta-analysis. Arch Intern Med 1999; 159:941-955
10. Boulet L-P. Perception of the role and potential side effects of inhaled corticosteroids among asthmatic patients. Chest 1998; 113:587-592
11. Jones C, Santanello NC, Boccuzzi SJ, et al. Adherence to prescribed treatment for asthma: evidence from pharmacy benefits data. J Asthma 2003; 40:93-101
12. World Health Organization. Asthma. In: Adherence to long-term therapies: evidence for action. Geneva, Switzerland: World Health Organization, 2003; 47-58
13. Derendorf H. Pharmacokinetic and pharmacodynamic properties of inhaled corticosteroids in relation to efficacy and safety. Respir Med 1997; 91(suppl):22-28
14. Kelly HW. Comparative potency and clinical efficacy of inhaled corticosteroids. Respir Care Clin N Am 1999; 5:537-553
15. Sharpe M, Jarvis B. Inhaled mometasone furoate: a review of its use in adolescents with persistent asthma. Drugs 2001; 61:1325-1350
16. 14C]ciclesonide after oral and intravenous administration to healthy subjects. Clin Pharmacokinet 2004; 43:479-486
17. Nave R, Bethke TD, Seiberling M, et al. Pharmacokinetics and pharmacodynamics of ciclesonide and its active principle after inhalative and intravenous administration in healthy subjects [abstract]. Eur Respir J 2002; 20:38
18. Rohatagi S, Derendorf H, Zech K, et al. PK/PD of inhaled corticosteroids: the risk/benefit of inhaled corticosteroid [abstract]. J Allergy Clin Immunol 2003; 111(suppl):S218
19. Ciclesonide [package insert] Konstanz, Germany: ALTANA Pharma
20. Derendorf H, Hochhaus G, Meibohm B, et al. Pharmacokinetics and pharmacodynamics of inhaled corticosteroids. J Allergy Clin Immunol 1998; 101:5440-5446
21. Dolovich M, Rhem R Impact of oropharyngeal deposition on inhaled dose. J Aerosol Med 1998; 11(suppl):S112-S115
22. Haley KJ, Sunday ME, Wiggs BR, et al. Inflammatory cell distribution within and along asthmatic airways. Am J Respir Crit Care Med 1998; 158:565-572
23. Miller-Larsson A, Mattsson H, Hjertberg E, et al. Reversible fatty acid conjugation of budesonide: novel mechanism for prolonged retention of topically applied steroid in airway tissue. Drug Metab Dispos 1998; 26:623-630
24. Smith CL, Kreutner W. In vitro glucocorticoid receptor binding and transcriptional activation by topically active glucocorticoids. Arzneimittelforschung 1998; 48:956-960
25. Daley-Yates PT, Price AC, Sisson JR, et al. Beclomethasone dipropionate: absolute bioavailability, pharmacokinetics and metabolism following intravenous, oral, intranasal and inhaled administration in man. Br J Clin Pharmacol 2001; 51:400-409
26. Nave R, Fisher R, Zech K. In vitro metabolism of ciclesonide in the human lung and liver as determined by use of precision-cut tissue slices [abstract]. Am J Respir Crit Care Med 2003; 167:A1510
27. Nave R, Meyer W, Fuhst R, et al. Formation of fatty acid conjugates of ciclesonicle-active metabolite in the rat lung after 4-week inhalation of ciclesonide. Pulm Pharmacol Ther 2005; 18:390-396
28. Phillipps GH, Bailey EJ, Bain BM, et al. Synthesis and structure-activity relationships in a series of anti-inflammatory corticosteroid analogues, halomethyl androstane-17beta-carbothioates and -17beta-carboselenoates. J Med Chem 1994; 37:3717-3729
29. Flixotide Accuhaler. Available at: http://emc.medicines.org. uk/emc/assets/c/html/displaydoc.asp?documentid = 86. Accessed May 15, 2006
30. Leach C. Effect of formulation parameters on hydrofluoroalkane- beclomethasone dipropionate drug deposition in humans. J Allergy Clin Immunol 1999; 104:S250-S252
31. Allen DB, Bielory L, Derendorf H, et al. Inhaled corticosteroids: past lessons and future issues. J Allergy Clin Immunol 2003; 112:S1-S40
32. Brattsand R, Miller-Larsson A. The role of intracellular esterification in budesonide once-daily dosing and airway selectivity. Clin Ther 2003; 25(suppl):C28-C41
33. Toogood JH, Jennings B, Baskerville J, et al. Dosing regimen of budesonide and occurrence of oropharyngeal complications. Eur J Respir Dis 1984; 65:35-44
34. Engelstätter R, Benezet O, Kafé H, et al. Comparative study in asthma patients treated with inhaled ciclesonide (80 μg or 320 μg once daily) or budesonide (200 μg twice daily) for 12 weeks [abstract]. Am J Respir Crit Care Med 2003; 167: A1511
35. Drollmann A, Hasselquist BE, Boudreau RJ, et al. Ciclesonide shows high lung deposition in 2D and 3D-imaging [abstract]. Am J Respir Crit Care Med 2002; 165: A188
36. Drollmann A, Nave R, Steinijans VW, et al. Equivalent pharmacokinetics of the active metabolite of ciclesonide with and without use of a spacer for inhalation [abstract]. J Allergy Clin Immunol 2004; 113:2
37. Leach CL, Davidson PJ, Hasselquist BE, et al. Lung deposition of hydrofluoroalkane-134a beclomethasone is greater than that of chlorofluorocarbon fluticasone and chlorofluorocarbon beclomethasone: a cross-over study in healthy volunteers. Chest 2002; 122:510-516
38. Agertoft L, Pedersen S. Lung deposition and systemic availability of fluticasone Diskus and budesonide Turbuhaler in children. Am J Respir Crit Care Med 2003; 168:779-782
39. Thorsson L, Edsbacker S, Conradson TB. Lung deposition of budesonide from Turbuhaler is twice that from a pressurized metered-dose inhaler P-MDI. Eur Respir J 1994; 7:1839-1844
40. Thorsson L, Edsbacker S, Kallen A, et al. Pharmacokinetics and systemic activity of fluticasone via Diskus and pMDI, and of budesonide via Turbuhaler. Br J Clin Pharmacol 2001; 52:529-538
41. Mutch E, Nave R, Zech K, et al. Esterases involved in the hydrolysis of ciclesonide in human tissues [abstract]. Eur Respir J 2003; 22:1749
42. Belvisi M, Bundschuh D, Stoeck M, et al. Ciclesonide, a novel On site activated' inhaled corticosteroid with potent antiinflammatory actions in the airways [abstract]. J Allergy Clin Immunol 2002; 109(suppl):59
43. Derendorf H. Pharmacokinetic and pharmacodynamic properties of inhaled corticosteroids in relation to efficacy and safety. Respir Med 1997; 91(suppl):22-28
44. Stoeck M, Riedel R, Hochhaus G, et al. In vitro and in vivo anti-inflammatory activity of the new glucocorticoid ciclesonide. J Pharmacol Exp Ther 2004; 309:249-258
45. Mobley JL, Chin JE, Richards IM. Glucocorticoids, old and new: biological function and use in the treatment of asthma. Expert Opin Invest Drugs 1996; 5:871-884
46. Barnes PJ, Pedersen S, Busse WW. Efficacy and safety of inhaled corticosteroids: new developments. Am J Respir Crit Care Med 1998; 157:S1-S53
47. Bundschuh DS, Riedel R, Hatzelmann A, et al. Efficacy and safety profile of the novel on-site activated corticosteroid ciclesonide [abstract]. Am J Respir Crit Care Med 2001; 163(5 Suppl):A588
48. Bundschuh DS, Marx D, Hatzelmann A, et al. Pre-clinical anti-inflammatory activity and safety profile of the novel glucocorticoid ciclesonide [abstract]. Eur Respir J 2001; 18(suppl):147s
49. Taylor DA, Jensen MW, Kanabar V, et al. A dose-dependent effect on the novel inhaled corticosteroid ciclesonide on airway responsiveness to adenosine-5-monophosphate in asthmatic patients. Am J Respir Crit Care Med 1999; 160: 237-243
50. Richter K, Kanniess F, Biberger C, et al. Comparison of the oropharyngeal deposition of inhaled ciclesonide and fluticasone propionate in patients with asthma. J Clin Pharmacol 2005; 45:146-152
51. Nave R, Zech K, Bethke TD. Lower oropharyngeal deposition of inhaled ciclesonide via hydrofluoroalkane metered-dose inhaler compared with budesonide via chlorofluorocarbon metered-dose inhaler in healthy subjects. Eur J Clin Pharmacol 2005; 61:203-208
52. Nave R, Hummel R-P, Wohlsen A, et al. The active metabolite of ciclesonide, des-isobutyryl ciclesonide, forms highly lipophilic fatty acid conjugates in precision-cut rat lung slices [abstract]. Am J Respir Crit Care Med 2004; 169:91
53. Bethke TD, Nave R, Zech K, et al. Pharmacokinetics of ciclesonide and its active principle in asthma patients and healthy subjects after single dose inhalation [abstract]. J Allergy Clin Immunol 2003; 111:593
54. Chapman KR, Patel P, D'Urzo AD, et al. Maintenance of asthma control by once-daily inhaled ciclesonide in adults with persistent asthma. Allergy 2005; 60:330-337
55. Postma DS, Sevette C, Martinat Y, et al. Treatment of asthma by the inhaled corticosteroid ciclesonide given either in the morning or evening. Eur Respir J 2001; 17:1083-1088
56. O'Connor BJ, Kilfeather S, Cheung D, et al. Treatment of moderate to severe asthma with ciclesonide: a long-term investigation over 52 weeks [abstract]. Eur Respir J 2002; 20(suppl):406S
57. Hansel TT, Biberger C, Engelstätter R. Ciclesonide 80 μg or 320 μg once daily achieves lung function improvement comparable with budesonide 200 μg twice daily in patients with persistent asthma [abstract]. Thorax 2004; 59(suppl):12
58. Ukena D, Biberger C, von Behren V, et al. Ciclesonide significantly improves pulmonary function when compared with budesonide: a randomized 12-week study [abstract]. Eur Respir J 2003; 22(suppl):S45
59. Lee DC, Fardon TC, Bates CE, et al. Airway and systemic effects of hydrofluoroalkane formulations of high-dose ciclesonide and fluticasone in moderate persistent asthma. Chest 2005; 127:851-860
60. Buhl R, Vinkler I, Magyar P, et al. Once daily ciclesonide and twice daily fluticasone propionate are equally effective in the treatment of patients with asthma [abstract]. Eur Respir J 2004; 24(suppl):346S
61. Derom E, Van De Velde V, Marissens S, et al. Effects of inhaled ciclesonide and fluticasone propionate on Cortisol secretion and airway responsiveness to adenosine 5′monophosphate in asthmatic patients. Pulm Pharmacol Ther 2005; 18:328-336
62. Berger W, Mansfield L, Pinter C, et al. Ciclesonide is well tolerated and has minimal oropharyngeal side effects at once-daily doses of 80 μg, 160 μg, and 320 μg in the treatment of adult/adolescent patients with mikl-to-moderate persistent asthma. Poster presented at AAAAI 2004; March 19-23, 2004; San Francisco, CA; abstract 50A
63. Bernstein J, Noonan M, Rim C, et al. Ciclesonide has minimal oropharyngeal side effects in the treatment of patients with moderate-to-severe asthma. Poster presented at AAAAI 2004; March 19-23, 2004; San Francisco, CA; abstract 349
64. Chapman KR, Boulet L-P, D'Urzo AD, et al. Long-term administration of Ciclesonide is safe and well tolerated in patients with persistent asthma. Abstract presented at 4th Triennial World Asthma Meeting 2004, February 16-19, 2004; Bangkok, Thailand
65. Newman S, Salmon A, Nave R, et al. High lung deposition of 99mTc-labeled ciclesonide administered via HFA-MDI to patients with asthma. Respir Med 2006; 100:375-384
66. Rohatagi S, Luo Y, Shen L, et al. Protein binding and its potential for eliciting minimal systemic side effects with a novel inhaled corticosteroid. Am J Ther 2005; 12:201-209
67. Nave R, Meyer W, Fuhst R, et al. Formation of fatty acid conjugates of ciclesonide active metabolite in the rat lung after 4-week inhalation of ciclesonide. Pulm Pharmacol Ther 2005; 18:390-396